More stories

  • in

    The 2022 CNBC Disruptor 50 list: Meet the next generation of Silicon Valley

    The 2022 CNBC Disruptors are 50 private companies growing and innovating through a challenging market and changed world, while inspiring change in their larger, incumbent competitors.

    In the tenth annual Disruptor 50 list, CNBC highlights private companies that grew through the ups and downs of the pandemic and are poised to meet increasing economic and consumer challenges.
    All told, these firms have raised a half-trillion dollars in venture capital. At least 41 are unicorns, with valuations of $1 billion or more – 14 are valued at over $10 billion. But becoming a unicorn has become all too common, and as market volatility pressures valuations in both public and private markets, other stats stand out: 

    Forty of the companies have a social or environmental purpose that is core to their business model. Ten of this year’s Disruptors are from the logistics sector, tackling the broken global supply chain that has fueled four-decade high inflation. Eight are reducing costs in a bloated health-care system and reaching underserved populations. Several more are dedicated to the climate crisis. Nine of this year’s Disruptors have a female founder. Sixteen feature CEOs from racial and ethnic minorities.  
    The 50 companies selected using the proprietary Disruptor 50 methodology have raised over $56 billion in venture capital, according to PitchBook, at an implied Disruptor 50 valuation of more than $552 billion.

    1
    Flexport
    Overwhelming the supply chain bottleneck

    2
    Brex
    The start-up world’s finance department

    3
    Lineage Logistics
    On top of the global food supply’s temperature

    4
    Canva
    The feature presentation

    5
    Guild Education
    Work. Study.

    6
    Convoy
    Trucking as we’ve known it stops here

    7
    Blockchain.com
    Web3’s dot com

    8
    Stripe
    Making the internet pay

    9
    Dapper Labs
    The shot Michael Jordan and Kevin Durant are taking on decentralization

    10
    Pony.ai
    Hand over the reins.

    11
    Checkout.com
    A rival to the Stripe swipe

    12
    Chime
    A challenger bank in a challenging fintech market

    13
    Discord
    How digital natives converse

    14
    Flock Freight
    Fully loaded

    15
    Medable
    The virtual clinical trial

    16
    Truepill
    The infrastructure for online pharmacy

    17
    Arctic Wolf
    A cyber defender from up north

    18
    CloudTrucks
    Big ideas for the Big Road

    19
    Maven Clinic
    Putting women first in health

    20
    Monarch Tractor
    1 driver. 8 tractors. All electric.

    21
    Fanatics
    Taking sports merch into the metaverse

    22
    Tala
    The world’s local lender

    23
    Anduril Industries
    Engineering an autonomous military arsenal

    24
    Workato
    Office work automated

    25
    Lacework
    Cybercrime’s lie detector

    26
    Somatus
    Kidney care without the dialysis centers

    27
    Gopuff
    All your instant needs fulfilled

    28
    Virta Health
    Don’t treat diabetes; reverse it.

    29
    Zipline
    A life-saving drone, with a Walmart side hustle

    30
    CarbonCure
    Carbon to concrete

    31
    Jüsto
    Mexico’s answer to Walmart, and FreshDirect, and Gopuff

    32
    Biobot Analytics
    A wastewater virus hunter

    33
    Airtable
    The code for every knowledge worker

    34
    Databricks
    The start-up world’s biggest data bet

    35
    DataRobot
    A one-trillion predictions market maker

    36
    Relativity Space
    An Elon Musk reusable rocket competitor

    37
    NEXT Insurance
    Digital small business insurance

    38
    Ro
    Planning to be a digital health survivor

    39
    Airspace
    Critical on-demand delivery for the pandemic era

    40
    Thrasio
    A consumer products giant for the digital age.

    41
    Cybereason
    A bird’s eye view

    42
    BlocPower
    Building net-zero cities

    43
    ŌURA
    The one ring to rule wearables

    44
    MoonPay
    The biggest celebrity bet on crypto

    45
    Zum
    School bus magic

    46
    Exotec
    France’s warehouse robot unicorn

    47
    Plaid
    A bridge from fintech to bank

    48
    Cityblock Health
    Healthtech for low-income America

    49
    Impossible Foods
    From plant-based fad to fixture

    50
    Envoy
    Back to the office of the future More

  • in

    26. Somatus

    The 2022 CNBC Disruptors are 50 private companies growing and innovating through a challenging market and changed world, while inspiring change in their larger, incumbent competitors.

    Founders: Ikenna Okezie (CEO), Tony WeltersLaunched: 2017Headquarters: McLean, VirginiaFunding: $490.1 million (PitchBook)Valuation: $2.5 billion (PitchBook)Key technologies: Artificial intelligence, machine learningIndustry: Health carePrevious appearances on Disruptor 50 List: 0

    Persephone Kavallines

    When Warren Buffett buys big into a stock, and keeps buying, it’s typically a sign that the billionaire investor thinks a company has close to monopoly-like power over some market. That’s the case with kidney care company DaVita, which Buffett’s Berkshire Hathaway started buying several years ago and in which it now holds a stake worth well north of 30%. DaVita is among a handful of companies that dominate the market for kidney care and dialysis. But big incumbents will also attract the attention of disruptive start-ups, sometimes starting out from with their own ranks.

    Somatus, a kidney care provider, was co-founded by former DaVita executive and doctor Ikenna Okezia, who is its CEO. Since 2016, Somatus has been building a network that works with health plans and provider groups to lower the cost of kidney care, using locally-based providers and in-home care for patients.
    The existing approach built by companies including DaVita relies on the physical infrastructure of bricks-and-mortar dialysis centers. With the heavy investment that went into building this system, start-ups see an opportunity in new, less real-estate intensive models.

    More coverage of the 2022 CNBC Disruptor 50

    Globally, there as many as two million people suffering from kidney failure, and the disease is increasing by 5% to 7% a year.
    In the U.S., specifically, kidney disease affects 15% of the U.S. adult population, over 37 million people, and disproportionately is suffered by the Black population and low-income Americans. This has led to criticism that the system has been allowed to remain as it is, in part due to the nature of the patient population. It’s a claim made by Andy Slavitt, former managing director of The Centers for Medicare & Medicaid Services under President Barack Obama, who has invested in several companies in the kidney care disruptor space through his VC firm Town Hall Ventures, including Somatus. He was previously on the Somatus board.
    According to critics, kidney care falls into the frustrating health care category of high costs and questionable outcomes. For severe cases, the price tag for dialysis is steep, with end-stage kidney disease patients paying as much as $15,000 per month, according to a recent study. The 750,000 Americans who live with kidney failure represent 7% of Medicare’s budget, with dialysis costing Medicare $90,000 per patient annually, a total running into the tens of billions of dollars. 

    As the status quo, high-cost incumbents are targeted, Somatus is in an increasingly crowded field of new companies in the kidney care space, which includes Strive Health, Cricket Health and Monogram Health. And the Somatus founder isn’t the only member of the “DaVita mafia” coming for their former employer.  Strive Health was founded by two former DaVita executives. DaVita and its peers including Fresenius are aware of the changes taking place in the market and are making their own investments in new approaches.
    Somatus continues to secure new capital from investors and notable health-care market deals. In February, it raised over $325 million in a Series E funding round at a valuation of over $2.5 billion, with investors including Wellington Management and Fidelity. In November of last year, Anthem made a strategic investment in Somatus, and announced a long-term, multi-year partnership to expand the company’s geographic footprint, which is expected to reach 35 states and 150,000 patients this year across Medicare, Medicare Advantage, Medicaid, and commercial plans.

    Sign up for our weekly, original newsletter that goes beyond the annual Disruptor 50 list, offering a closer look at list-making companies and their innovative founders. More

  • in

    28. Virta Health

    The 2022 CNBC Disruptors are 50 private companies growing and innovating through a challenging market and changed world, while inspiring change in their larger, incumbent competitors.

    Founders: Sami Inkinen (CEO), Stephen Phinney, Jeff VolekLaunched: 2015Headquarters: San FranciscoFunding: $366 millionValuation: $2 billionKey technologies: Artificial intelligence, machine learningIndustry: Health carePrevious appearances on Disruptor 50 List: 1 (No. 29 in 2019)

    Persephone Kavallines

    Virta Health’s origin story is well-known: Sami Inkinen, founder of real estate start-up Trulia, a fitness enthusiast and Ironman competitor, discovered to his surprise he was pre-diabetic and decided in 2014 to do something about it. As a start-up entrepreneur, he co-founded Virta Health with the mission of reversing type 2 diabetes in 100 million people by 2025.

    There are 34 million Americans living with diabetes and 88 million who are pre-diabetic at an annual cost of well over $300 billion to the U.S. economy, and that cost has been increasing fast in recent years, according to the American Diabetes Association.
    Drugs treating diabetes by keeping blood sugar levels under control have been the health-care norm and major drug companies have made a fortune, with U.S. sales reaching $74 billion in 2020, up from just $7 billion two decades ago, according to IQVIA data cited by Reuters. Type 2 diabetes is also linked closely to additional business models in the obesity market, from weight loss companies and apps to bariatric surgery. 

    More coverage of the 2022 CNBC Disruptor 50

    Many patients are told to eat less and exercise more, but Virta Health aims to upend the status quo in general wellness advice, combined with drug reliance. Using technology to connect patients with coaching and remote care, as well as nutritional science, it wants to change the way the medical community thinks about diabetes as a chronic condition — reversing the disease rather than poorly managing it and exposing patients to the additional risks that go along with medication. 
    The company raised another $133 million last April, nearly doubling its valuation to $2 billion. But it isn’t alone in promoting a new technology-led model for chronic health conditions, with Teladoc (it acquired chronic care company Livongo), Omada Health, and Onduo among rivals that have seen increased funding and partnerships. 
    What sets Virta apart from its competitors is going beyond managing the disease through technology, to seeking actual reversal of it. Each patient has a remote care team — a health coach and a medical provider, and receives behavioral support and encouragement from their coaches and an online community of their peers. Early-adopters have been vocal advocates for its approach: one profiled by CNBC in 2020 tattooed the company’s logo on her arm. But the science remains young and the research limited.

    Part of its approach requires a drastic reduction in carbohydrate calories (the science of nutritional ketonosis), and it has yet to be proven that this is a sustainable approach for long-term diabetes management. Virta clinical trial results from 2019, while showing both reversal and in other cases remission of diabetes, only cover a few years of treatment. In 2021, it published peer-reviewed research on Virta’s treatment of prediabetes, showing that only 3% of trial participants progress to type 2 diabetes during the first two years. Additional research has shown that its approach can reduce another byproduct of diabetes: depression in patients on conventional treatment.
    The Virta Health model is being embraced by more corporate health care plans, health systems and insurers. Virta has expanded to over 200 customers as of late last year, including major insurers Providence Health Plan and Humana, which signed a deal last year to offer Virta’s diabetes reversal treatment to employer groups. It now works with more than 20 national and regional health plans, marking 133% year-over-year growth with large insurer customers, nearly half of which now offer Virta’s diabetes reversal treatment to their employer groups. That represents thousands of companies and over five million individuals. The company is growing its staff to keep up with the deals, doubling headcount to 400-plus employees in 2021. 
    The approach is gaining more acceptance from the academic community, if not by specific name in the case of Virta, at least in terms of the concept of reversing the disease as medical aim. In August of last year, the American Diabetes Association, the Endocrine Society, the European Association for the Study of Diabetes, and Diabetes UK released a consensus report that defined diabetes reversal for the first time.

    Sign up for our weekly, original newsletter that goes beyond the annual Disruptor 50 list, offering a closer look at list-making companies and their innovative founders. More

  • in

    A huge tidal power testing facility is looking to simulate decades of harsh sea conditions

    Sustainable Energy

    Sustainable Energy
    TV Shows

    A £4.6 million ($5.64 million) facility that can test tidal turbine blades under strenuous conditions has been officially opened.
    The University of Edinburgh says the site is the “world’s first rapid testing facility for tidal turbine blades.”
    While there is excitement about the potential of marine energy, the footprint of tidal stream and wave projects remains very small compared to other renewables.

    An image of the £4.6 million FastBlade facility. Scotland has a long association with North Sea oil and gas production, but in recent years it’s also become a hub for companies and projects focused on tidal power and marine energy in general.
    Jeff J Mitchell | Getty Images News | Getty Images

    A £4.6 million ($5.64 million) facility that can test tidal turbine blades under strenuous conditions has been officially opened, with those behind it hoping it will accelerate the development of marine energy technology and lower costs.
    In a statement at the end of last week, the University of Edinburgh said the site was the “world’s first rapid testing facility for tidal turbine blades.”

    It added that the FastBlade facility would use a 75 metric ton reaction frame that was able to apply “powerful forces on turbine blades more than 50 feet long.”
    FastBlade is a partnership between aerospace firm Babcock International and the university that’s backed by a grant of £1.8 million from the U.K. government. The testing center is located in the town of Rosyth.
    Tests on blades, the university said, would be undertaken “using a system of powerful hydraulic cylinders, which, in less than three months, can simulate the stresses placed on the structures during two decades at sea.”
    Conchúr Ó Brádaigh, who is head of the university’s school of engineering, said FastBlade would be “the world’s first dedicated fatigue test facility for tidal turbine blades.”
    He went on to state it would also “help maintain the globally leading position of Scottish tidal turbine developers in the race to find sources of clean and secure power.”

    The University of Edinburgh said the FastBlade technology could also be harnessed to test wing components for aircraft and lightweight bridge sections.

    Read more about energy from CNBC Pro

    Scotland has a long association with North Sea oil and gas production, but in recent years it’s also become a hub for companies and projects focused on tidal power and marine energy in general.
    These firms include tidal energy firm Nova Innovation and Orbital Marine Power, which is working on what it says is the “most powerful tidal turbine in the world.”
    In waters north of the Scottish mainland, the archipelago of Orkney is home to the European Marine Energy Centre, or EMEC, where wave and tidal energy developers can test and assess their tech in the open sea.
    European installations of tidal and wave energy capacity jumped in 2021, as the ocean energy sector saw deployments revert to pre-pandemic levels and a substantial increase in investment.
    In March, Ocean Energy Europe said 2.2 megawatts of tidal stream capacity was installed in Europe last year, compared to just 260 kilowatts in 2020. For wave energy, 681 kW was installed, which OEE said was a threefold increase.
    Globally, 1.38 MW of wave energy came online in 2021, while 3.12 MW of tidal stream capacity was installed. Capacity refers to the maximum amount of electricity installations can produce, not what they’re necessarily generating.While there is excitement about the potential of marine energy, the footprint of tidal stream and wave projects remains very small compared to other renewables.
    In 2021 alone, Europe installed 17.4 gigawatts of wind power capacity, according to figures from industry body WindEurope. More

  • in

    Some factories might leave China, but in the grand scheme of things it doesn't matter much

    China’s tight Covid controls have reignited conversations about moving supply chains out of the country.
    “From China’s perspective, the movement out of local manufacturing is not going to be significant enough to really alter the nature of China’s role in the overall supply chain,” Vishrut Rana, Singapore-based economist at S&P Global Ratings, said in a phone interview.
    For the first four months of the year, foreign direct investment into China rose by 26.1% year-on-year to $74.47 billion, China’s Ministry of Commerce said, with that from the U.S. up by more than 50%.

    China still holds the cards for global supply chains, whether or not Covid lockdowns frustrate businesses in the near term. An employee works on the production line of the screens for 5G smartphones at a factory on May 13, 2022 in Ganzhou, Jiangxi Province of China.
    Zhu Haipeng | Visual China Group | Getty Images

    BEIJING — China still holds the cards for global supply chains, whether or not Covid lockdowns frustrate businesses in the near term.
    Companies and analysts have discussed moving factories out of China for years, especially since labor costs have climbed and U.S.-China trade tensions worsened.

    The pandemic has reignited those conversations. Foreign businesses talk about how executives can easily travel to Southeast Asia factories, but not China. Some point to surging exports from Vietnam as an indicator that supply chains are leaving China.
    “Supply chain diversification is quite tricky because people always talk about it, and boardrooms love to discuss it, but often at the end of the day people find it’s difficult to implement,” said Nick Marro, global trade leader at The Economist Intelligence Unit.
    When businesses had those discussions in 2020, it turned out that “China was able to remain open, while Malaysia, Vietnam were going offline,” Marro said. “Really, the critical factor right now is how China plans on maintaining these [Covid] controls as the rest of the world opens up.”

    China’s so-called zero-Covid strategy of swift lockdowns helped the country quickly return to growth in 2020. However, implementation of those measures has since tightened, especially this year as China faces a resurgence of Covid in Shanghai and other parts of the country.

    ‘Significant’ interest in Vietnam

    By the numbers, China’s exports rose by 3.9% in April from a year earlier, the slowest pace since a 0.18% increase in June 2020, according to official data accessed through Wind Information.

    Vietnam in contrast saw exports jump by 30.4% in April from a year ago, following a nearly 19.1% year-on-year increase in March, Wind showed.
    The level of manufacturing interest in Vietnam is “very significant,” Vishrut Rana, Singapore-based economist at S&P Global Ratings, said in a phone interview. “Vietnam has emerged as a very key supply chain node for consumer electronics.”

    China still remains at the very center of the electronics network in APAC.

    Vishrut Rana
    Economist, S&P Global Ratings

    But Vietnam’s exports totaled $33.26 billion in April, or about one-eighth of China’s $273.62 billion in global exports that month, according to Wind.
    “From China’s perspective, the movement out of local manufacturing is not going to be significant enough to really alter the nature of China’s role in the overall supply chain,” Rana said. “China still remains at the very center of the electronics network in APAC.”

    Businesses still invest in China

    For the first four months of the year, foreign direct investment into China rose by 26.1% year-on-year to $74.47 billion, China’s Ministry of Commerce said Thursday. During that time, investment from Germany jumped by 80.4%, while that from the U.S. rose by 53.2%.
    In contrast, Vietnam saw a 56% year-on-year drop in foreign direct investment to $3.7 billion in the first four months of the year, Wind data showed. Foreign direct investment from the U.S. fell by 14%.

    The latest Covid lockdowns in China have slowed the ability of trucks to transport goods throughout China, while keeping many factories in the Shanghai region at limited or no production for weeks. Pictured here is a textile company’s workshop in the nearby Jiangsu province.
    CFOTO | Future Publishing | Getty Images

    “It is very difficult to match the scale and scope of China’s supply chains outside China at the moment,” Rana said. Only supply chains for very specific products — like semiconductors or electric vehicle parts —might be moving to Vietnam, Malaysia or other countries, he added.
    China’s supply chain dominance, built up over the years, is also supporting new business models.
    One of the better known is Shein. Backed by funds such as Sequoia Capital China, the company has combined big data analytics and its supply chain network in China to become an international e-commerce giant in low-cost fast fashion.
    “China’s supply chain advantage is not just based on labor cost,” James Liang, managing partner at Skyline Ventures, said in Mandarin translated by CNBC.

    According to his analysis, at least 20% of the selling price of apparel and furniture producers go into labor costs, versus just 5% for electronics producers.
    China’s advantage is the benefit of having supply chain hubs, which in Liang’s view pave the way for businesses to boost efficiency by integrating all their suppliers onto one digital system.
    He said his firm invested $5 million in October into a furniture company called Povison, which is trying to replicate Shein’s model for clothing. Additional investment plans have been delayed due to Covid-related travel restrictions, he said.

    ‘A story of hesitation’

    The latest Covid lockdowns have also slowed the ability of trucks to transport goods throughout China, while keeping many factories in the Shanghai region at limited or no production for weeks. That’s on top of Beijing’s policy since 2020 requiring two- or three-week quarantine upon arrival in China — if the traveler can book one of the few flights in.
    Shifting operations out of China is difficult, but “what our survey is indicating is there will be less investment into China and more investment into Southeast Asia,” Joerg Wuttke, president of the EU Chamber of Commerce in China, said during a webinar.

    He noted how it is now far easier to fly executives to Singapore or other countries in the region, than to China.
    As a result of the latest Covid controls, nearly a quarter of 372 respondents to the EU Chamber of Commerce in China’s survey in late April said they were considering shifting current or planned investments to other markets.
    But 77% said they didn’t have such plans. A survey of U.S. businesses in China found similar trends.
    Those survey results indicate that “companies don’t want to quit the market, but they don’t know what to do,” said the EIU’s Marro. “Right now it’s more a story of hesitation.”
    “Foreign companies are going to be upset about these [zero-Covid] policies, but at the end of the day there’s not many companies that are going to jeopardize their position in a decades-long market based on a temporary shock,” he said.

    Read more about China from CNBC Pro

    Even companies like Starbucks, which suspended guidance due to Covid unpredictability, said it still expects its China business will become bigger than the U.S. in the long term.
    Many analysts expect China may begin to relax its zero-Covid policy after a political reshuffle in the fall.
    When asked Thursday about the EU Chamber’s survey findings, China’s Ministry of Commerce only noted the global impact of the pandemic to supply chains. The ministry also said China would improve its foreign investment services and increase opportunities for foreign businesses.
    “Reconfiguring supply chains is not as easy as flipping a light switch on and off,” said Stephen Olson, senior research fellow at the Hinrich Foundation.
    “Of course, the chessboard would be reconfigured if lockdowns drag on indefinitely,” he said. “In that case, pressure will build on companies to consider shifting supply patterns, and the economic and commercial implications of doing so will look a lot more favorable.”

    WATCH LIVEWATCH IN THE APP More

  • in

    Home affordability at 2007 bubble levels, but crash is unlikely: Blackstone's Joe Zidle

    Monday – Friday, 5:00 – 6:00 PM ET

    Fast Money Podcast
    Full Episodes

    A major Wall Street firm is drawing a striking parallel to the housing bubble.
    Blackstone’s Joe Zidle calls homes almost as unaffordable as the 2007 peak. Yet, he believes a crash is unlikely due to a major difference: Most owners aren’t using their homes like an ATM.

    “That caused so many people to go upside down,” the firm’s chief investment strategist told CNBC’s “Fast Money” on Monday. “The value of what they owed was greater than the value of their home.”
    Unlike the housing bust, Zidle adds home equity is at an all-time high and household balance sheets are strong.
    “You haven’t had overbuilding. You haven’t had a drop in credit or lending standards,” he noted.
    Blackstone is known for buying scores of distressed residential properties tied to the 2008 financial crisis. It’s still a major player in real estate, with investments in rentals, the rent-to-buy market and student housing.
    “Because you have very little excess in housing, I think you end up having less risk,” he said.

    Plus, Zidle cites a strong jobs market.
    “Historically, housing ends up being more highly correlated to labor markets than it is to mortgage rates,” he said. “As long as the jobs market remains relatively healthy, I think housing will as well.”
    His forecast comes as Wall Street gets ready for key reports this week on the consumer and housing. Investors will get earnings from major retailers including Walmart, Home Depot, Lowe’s and Target. Plus, numbers on homebuilder sentiment and home sales are due.

    Arrows pointing outwards

    Zidle’s call reflects a 12-month time frame. Within that horizon, he sees the Federal Reserve hiking interest rates deeper into next year than the Street anticipates due to persistent inflation.
    “Ultimately, the Fed is going to have to hike interest rates until something breaks,” added Zidle. “When we do get to a point where something breaks, I don’t think it’s housing.”
    He expects the benchmark 10-year Treasury Note yield to hit 3.5%. It’s a level he expects the housing market to handle. On Monday, it was around 2.8%, up 90% so far this year.
    “You might see home prices generally flatten out. You may have pockets of weakness where home prices in some regions might fall,” Zidle said. “But the idea of having a national and a prolonged drop in housing as the economy eventually rolls over, I think is still a relatively low probability.”
    Disclaimer

    WATCH LIVEWATCH IN THE APP More

  • in

    Stock futures are flat after S&P, Nasdaq start the week in the red

    U.S. stock index futures were flat during overnight trading on Monday, following a volatile session that saw the S&P 500 and Nasdaq Composite continue their march lower.
    Futures contracts tied to the Dow Jones Industrial Average were flat. S&P 500 futures were slightly higher, while Nasdaq 100 futures added 0.13%.

    During regular trading the S&P dipped 0.39%. In a volatile session the benchmark index at one point gained 0.56%, while shedding about 1% at the session low.
    The Dow Jones Industrial Average saw a similar swing, although the 30-stock index eked out a 0.8% gain at the closing bell, pushed higher by Chevron and UnitedHealth.
    The Nasdaq Composite, meantime, was the session’s underperformer as the carnage in tech stocks continued. The tech-heavy index finished the day 1.2% lower, and is now 28% below its intraday all-time high from Nov. 22.
    “In a sense, the poor performance this year for tech and growth companies is somewhat of a payback for the impressive returns these market segments had recently enjoyed,” UBS said Monday in a note to clients.
    The tailwinds of the pandemic — a jump in stay-at-home spending and low interest rates — have since turned to headwinds. Now, consumer spending is shifting and rates are rising.

    “While we think that long-term interest rates have peaked for now, growth stocks are still expensive relative to value stocks,” UBS added.
    Investors will also be watching key economic data out Tuesday, with retail sales numbers hitting at 8:30 a.m. ET followed by industrial production numbers later in the morning.

    Stock picks and investing trends from CNBC Pro:

    Inflation concerns have been a mounting headwind for stocks, with some investors worried the economy could ultimately tip into a recession.
    “We see clear late-cycle indicators, and while the risk of economic growth contraction or recession has risen steadily through the first four-and-a-half months of this year, we are now beginning to cross over a probability level that makes recession a base case for the end of this year and beginning of next,” Darrell Cronk, president of Wells Fargo Investment Institute wrote in a note Monday.
    The firm added that ultimately it should be a “relatively mild economic growth contraction and a short-lived one.”
    While the bulk of earnings season is in the rearview mirror, a number of companies are on deck for Tuesday, including Walmart, Home Depot and JD.com.
    As of Friday afternoon, of the more than 90% of the S&P 500 that’s posted quarterly results, 78% of companies have beat earnings expectations while 75% have topped revenue forecasts, according to data from Refinitiv.

    WATCH LIVEWATCH IN THE APP More

  • in

    Abbott reaches agreement with FDA to reopen baby formula plant to ease nationwide shortage

    Under a consent decree, Abbott has agreed to address insanitary conditions that led to the contamination of its baby formula plant in Sturgis, Michigan.
    Abbott said it can restart the plant within two weeks.
    However, it would take six to eight weeks from the start of production for formula to arrive on store shelves, the company noted.

    A woman shops for baby formula at Target in Annapolis, Maryland, on May 16, 2022, as a nationwide shortage of baby formula continues due to supply chain crunches tied to the coronavirus pandemic that have already strained the countrys formula stock, an issue that was further exacerbated by a major product recall in February.
    Jim Watson | AFP | Getty Images

    Abbott reached an agreement with the Food and Drug Administration on Monday to reopen the company’s manufacturing plant in Michigan to help ease a nationwide shortage of baby formula, after the facility was closed due to bacterial contamination.
    FDA Commissioner Robert Califf said Abbott, under the conditions of the agreement, will correct insanitary conditions that led to the contamination and plant closure.

    “The public should rest assured that the agency will do everything possible to continue ensuring that infant and other specialty formulas produced by the company meet the FDA’s safety and quality standards,” Califf said in a statement.
    The agreement between Abbott and the FDA, called a consent decree, was approved by the U.S. District Court for the Western District of Michigan on Monday. Abbott can restart the Sturgis, Michigan, plant within two weeks, the company said. However, it said it would take six to eight weeks from the start of production for formula to arrive on store shelves.
    Mothers are struggling to find formula for their infants with shelves empty in many stores across the U.S. More than 40% of baby formula was out of stock nationwide during the week ended May 8, according to Datasembly, a retail data tracker. However, the FDA said Monday that nearly 80% of baby formula was in stock, citing data from Information Resources, another retail data company.
    The supply shortage was triggered in part by the closure of Abbott Nutrition’s manufacturing plant in Michigan after four infants who consumed formula from the facility fell ill from bacterial infections, two of whom subsequently died. Abbott is the largest infant formula manufacturer in the U.S.
    The Justice Department, in a complaint on behalf of the FDA, alleged that products manufactured at Abbott’s Sturgis facility were adulterated because they were made under insanitary conditions. 

    Inspections by the FDA found the presence of Cronobacter sakazakii, a bacteria that can cause blood infection, at the factory. Abbott internal records also showed that the company destroyed some of its product due to the presence of the bacteria at the plant, according to the FDA.
    Under the consent decree to reopen the plant, Abbott has agreed to bring in outside experts to help the facility come into compliance with food safety regulations, according to the Justice Department. The outside experts will design a plan for Abbott to reduce the risk of bacterial contamination at the plant and conduct periodic evaluations to make sure the company is in compliance. The process will be under FDA supervision, according to the Justice Department.
    Abbott is required to shut down production again if any products test positive for Cronobacter or Salmonella, dispose of the product, find the contamination source and correct the problem. The company cannot restart production again until it receives clearance from the FDA. If Abbott fails to comply, it would face $30,000 in damages for every day it’s in violation with the annual penalties not exceeding $5 million. The company is subject to the conditions of the consent decree for at least five years.
    Attorney General Merrick Garland, in a statement Monday, said the Justice Department would vigorously enforce U.S. food safety laws.
    In February, Abbott issued a voluntary recall of its Similac PM 60/40, Similac, Alimentum and EleCare products made at the Michigan plant. Abbott said last week that no formula distributed from the plant to consumers tested positive for the bacteria, and genetic sequencing of two samples from the sick infants did not match the Cronobacter strains found in the plant.
    The FDA concluded its inspection in March. The Centers for Disease Control and Prevention has found no additional cases of infants infected with Cronobacter after consuming products from the Michigan facility.
    The FDA, in a statement Monday, said it is working with other baby formula manufacturers to increase domestic production. Gerber increased the amount of formula available to consumers by 50% in March and April, and Reckitt has increased formula supply by more than 30% so far this year, according to the drug regulator. 
    The FDA said it will also increase baby formula imports to the U.S., which normally produces 98% of the formula that consumers buy. The drug regulator will allow the importation of formula originally produced for foreign markets, but manufacturers will have to submit applications to the FDA, which will evaluate whether the product is safe and provides enough nutrition.
    The FDA added it will prioritize applications from companies that demonstrate safety and nutritional standards and can expedite large quantities of their products to U.S. shelves. Senior Biden administration officials, in a call with reporters, said imported formula will come from countries with similar regulatory standards, such as Ireland, the U.K., Australia and New Zealand.
    The drug regulator said it also has been increasing the supply of baby formula arriving at the nation’s ports since February, with imports up more than 300% compared to last year. The FDA has been working with the U.S. Department of Agriculture and authorities in the U.K. and Europe on these imports.

    CNBC Health & Science

    Read CNBC’s latest global coverage of the Covid pandemic:

    WATCH LIVEWATCH IN THE APP More